[ARS] NRX Pharmaceuticals, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

Rhea-AI Filing Summary

Analyzing...

02/23/2026 - 05:15 PM

ARS - NRX Pharmaceuticals, Inc.

ARS Filing - NRX Pharmaceuticals, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: NRX Pharmaceuticals, Inc. (NRXP)

Acceptance Date: 2026-02-23T17:15:46.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Nrx Pharmaceuticals Inc

NASDAQ:NRXP

NRXP Rankings

#5508 Ranked by Market Cap

N/A Ranked by Dividends

#92 Top Loser

NRXP Latest News

Feb 17, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Jan 16, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

Jan 15, 2026

Bright Mountain Media Showcases Award-Winning Aruba Campaign; CEO Demonstrates Confidence with Stock Acquisition

Jan 14, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

Jan 5, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

NRXP Latest SEC Filings

Feb 23, 2026

[DEF 14A] NRX Pharmaceuticals, Inc. Definitive Proxy Statement

Feb 17, 2026

[Form 4] NRX Pharmaceuticals, Inc. Insider Trading Activity

Feb 17, 2026

[Form 3] NRX Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Feb 17, 2026

[8-K] NRX Pharmaceuticals, Inc. Reports Material Event

Feb 17, 2026

[8-K] NRX Pharmaceuticals, Inc. Reports Material Event

NRXP Stock Data

Market Cap 56.55M

Float 25.35M

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City WILMINGTON